

# Professional Background

- University of Illinois at Chicago
  - Director, Center for Health Statistics
  - Professor of Biostatistics, Psychiatry, and Mathematics, Statistics, and Computer Science
- Ph.D., Statistics and Psychometrics  
(University of Chicago, 1981)
- Author, more than 200 peer-reviewed scientific papers, five books

# Professional Recognition

- Harvard Award for Lifetime Contributions to Psychiatric Epidemiology and Biostatistics (2003)
- Outstanding Statistical Application Award for Contribution to Drug Safety, American Statistical Association (2009)
- Youden Award, American Statistical Association for Statistical Contributions to Chemistry (2001, 2006)
- Fellow, American Statistical Association
- Member, Institutes of Medicine (IOM), National Academy of Sciences (NAS)
- FDA Advisory Board on Suicide and Antidepressants in Adolescents (2004); Safety Science Board, FDA Sentinel Network (2010)
- National Institutes of Mental Health (NIMH), Research Scientist Award (1995-2000)
- Veterans Administration, Blue Ribbon Working Group on Suicide Prevention (2008)

# Dr. Gibbons' Opinions


- FDA study does not show that gabapentin causes suicidal thoughts or behavior
- Published AED study in bipolar patients: Shows 11 AEDs in the FDA study, including gabapentin, do not increase the risk of suicide attempts
- Gabapentin study: Gabapentin does not increase the risk of suicide attempts in any patient group
- There is no statistical basis for a gabapentin suicide warning

# Dr. Gibbons' Criticisms of FDA 2008 Study


- FDA finding of increased risk was driven by two drugs – topiramate and lamotrigine
- FDA excluded all studies with zero events
- FDA's conclusions regarding increased risk of AEDs cannot be applied to gabapentin
- FDA's conclusions regarding increased risk of AEDs do not apply to all patients

# FDA Cases of Suicidal Thinking or Behavior by Drug

Gabapentin studies – placebo treatment:  
1 event/2,029 patients




# FDA Meta-Analysis: Odds Ratios for All AEDs




Case 3:05-cv-00444 Document 174-2 Filed 04/27/10 Page 6 of 26 PageID# 4006

Source: Based on May 23, 2008 FDA Statistical Review and Evaluation of Antiepileptic Drugs and Toxicity, Figure 2, Pg. 24

# Rate of Suicidal Thinking and Behavior for Topiramate and Lamotrigine vs. Other Nine AEDs




# Rate of Suicidal Thinking and Behavior for Topiramate and Lamotrigine vs. Other Nine AEDs






# Gabapentin vs. Topiramate and Lamotrigine


## Risk Differences Relative to Placebo



# Gabapentin vs. Topiramate and Lamotrigine



# FDA Meta-Analysis: Risk Differences for All AEDs



Case 3:05-cv-00444 Document 174-2 Filed 04/27/10 Page 11 of 26 PageID #: 4011


Source: Based on May 23, 2004 FDA Statistical Review and Evaluation of Antiepileptic Drug: a011cidity, Figure 4, Pg. 26

# FDA Excluded Studies With Zero Events

- Biases FDA findings toward increased risk
- Ignores significant information about safety
- Creates uncertainty as to drug effect
- Including all gabapentin data gives a more precise picture and confirms no risk

# FDA Conclusions Cannot Be Applied to Gabapentin

## Actual Events Far Fewer Than Expected



Case 3:05-cv-00444 Document 174-2 Filed 04/27/10 Page 13 of 26 PageID #: 4018

Source: Based on May 22, 2008 FDA Draft Risk Review and Evaluation of Antiepileptic Drugs and Suicidality, Pg. 26

# Patient Groups With No Evidence Of Increased Risk

## Patient Group

Gabapentin Patients → NO

---

North Americans → NO

---

Psychiatric Patients → NO


---

Women → NO

---

In-Patients → NO


# Topiramate Drove FDA Finding on GABA Drug Group



Case 3:05-cv-00444 Document 174-2 Filed 04/27/10 Page 15 of 26 PageID #: 4015


Source: Based on May 23, 2008 FDA Public Review and Evaluation of Topiramate Drug: a 4015

# Topiramate Drove FDA Finding on GABA Drug Group





# Topiramate Drove FDA Finding on GABA Drug Group



Case 3:05-cv-00444 Document 174-2 Filed 04/27/10 Page 17 of 26 PageID #: 4017

Source: Based on May 23, 2008 FDA Public Review and Evaluation of Antiepileptic Drugs and Antiepileptic Drug Addictivity, Figure 7, Pg. 32

# FDA Acknowledges Limitations of Meta-Analysis

**DR. TWYMAN:** I have a question for the statisticians. Let's assume that the effect is generalizable to the class of AEDs. But, if you look at the compounds individually, could one draw the conclusion individually that compounds have a risk, or **do you need the entire data set of all the AEDs put together in order to draw the conclusion that AEDs have a signal?**

**DR. LEVENSON:** I would say that we need the entire data set in this case.

# Gibbons, et. al 2009 Bipolar Study

## ARCHIVES OF GENERAL PSYCHIATRY

Word Count: 4343  
Tables: 3  
Figures: 2

### The Relationship Between Antiepileptics and Suicide Attempts in Patients with Bipolar Disorder

Robert D. Gibbons<sup>1</sup>  
Kwan Hur<sup>1,2</sup>  
C. Hendricks Brown<sup>1,3</sup>  
J. John Mann<sup>4</sup>

<sup>1</sup>Center for Health Statistics, University of Illinois at Chicago  
Rooms 455-457 (MC 912), 1601 W. Taylor, Chicago, IL 60612, USA

<sup>2</sup>Cooperative Studies Program Coordinating Center,  
Hines VA Hospital, Hines, IL 60141

<sup>3</sup>Prevention Science and Methodology Group,  
Center for Family Studies, Department of Epidemiology and Public Health, University of  
Miami, 1425 N.W. 10th Avenue, Miami, Florida 33136

<sup>4</sup>Department of Neuroscience, New York State Psychiatric Institute  
Department of Psychiatry, Columbia University College of Physicians & Surgeons  
1051 Riverside Drive, New York, NY 10032, USA

March 2009

#### Corresponding Author:


Robert D. Gibbons, Ph.D.  
Director, Center for Health Statistics  
University of Illinois at Chicago  
1601 W. Taylor  
Chicago, IL 60614  
Phone: (312) 413-7755  
Fax: (312) 996-2113  
Email: [rdg@uic.edu](mailto:rdg@uic.edu)

**Acknowledgments:** This work was supported by NIMH grants MH062185 (JMM) and R56 MH078580 (RDG and CHB), and MH40859 (CHB) and AHRQ grant 1U18HS016973 (RDG). Dr. Gibbons has served or is currently serving as an expert witness for the U.S. Department of Justice, Wyeth and Pfizer Pharmaceuticals, the latter involving gabapentin, one of the drugs considered in this paper. Dr. Mann has received research support from GlaxoSmithKline and has served as an adviser to Eli Lilly and Lundbeck Pharmaceuticals. Dr. Brown directed a suicide prevention program at the University of South Florida that received funding from JDS Pharmaceuticals. Dr. Hur

## *The Relationship Between Antiepileptics and Suicide Attempts in Patients with Bipolar Disorder*


# Gibbons, et. al 2009 Bipolar Study

**Suicide Attempt Rate Almost Six Times Lower After AED Treatment Begins**




Case 3:05-cv-00444 Document 174-2 Filed 04/27/10 Page 20 of 26 PageID #: 4020

# Gibbons, et. al 2009 Bipolar Study



# Gibbons, et. al 2009 Bipolar Study




Adjusted for age, sex, concomitant medication, previous suicide attempt and year

Case 3:05-cv-00444 Document 174-2 Filed 04/27/10 Page 22 of 26 PageID #: 4022

# Person-Time Analysis of Highest Risk Group – Bipolar Patients With Suicide Attempt in Prior Year


- Restricting analysis to only those patients (n = 662) who made a suicide attempt in the year prior to the index diagnosis had odds ratio of 0.35 (0.17-0.74,  $p < 0.005$ )

# Gibbons Gabapentin Study: Analysis by Group







# Gibbons Gabapentin Study: Person-Time Analysis



# Gibbons Gabapentin Study: Risk of Suicide Attempt by Group

| Patient Group    | Result   |
|------------------|--|
| Bipolar          |  Decreased Risk |
| Major Depression |  Decreased Risk |
| Epileptic        | <b>No</b> Increased Risk   |
| Pain             | <b>No</b> Increased Risk   |
| All Patients     | <b>No</b> Increased Risk   |